VENTOLIN NEBULES P.F. - 5MG/2.5ML SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

SALBUTAMOL (SALBUTAMOL SULFATE)

متاح من:

GLAXOSMITHKLINE INC

ATC رمز:

R03AC02

INN (الاسم الدولي):

SALBUTAMOL

جرعة:

5MG

الشكل الصيدلاني:

SOLUTION

تركيب:

SALBUTAMOL (SALBUTAMOL SULFATE) 5MG

طريقة التعاطي:

INHALATION

الوحدات في الحزمة:

2.5ML DOSE X 20

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0108887001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2022-07-05

خصائص المنتج

_ _
_ _
_Page 1 of 33_
_ _
PRODUCT MONOGRAPH
PR
VENTOLIN
RESPIRATOR SOLUTION
salbutamol sulfate solution
5 mg/mL
PR
VENTOLIN NEBULES P.F.
salbutamol sulfate solution
2.5 mg/2.5 mL, 5 mg/2.5 mL ampoules
Bronchodilator
(beta
2
-adrenergic agonist)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
November 17, 2017
Submission Control No: 207158
© 2017 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK
group of companies.
_ _
_ _
_Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
.........................................................